<DOC>
	<DOCNO>NCT02290951</DOCNO>
	<brief_summary>This open-label , multi-center , dose escalation study REGN1979 administer IV ( intravenous ) infusion . This phase 1 study investigate safety tolerability REGN1979 patient Non-Hodgkin 's Lymphoma ( NHL ) Chronic Lymphocytic Leukemia ( CLL )</brief_summary>
	<brief_title>A Phase 1 Study Investigate Safety Tolerability REGN1979 Patients With CD20+ B-Cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Key 1 . Have document CD20+ Bcell malignancy , active disease responsive prior therapy , standard care option exist , treatment antiCD20 antibody may appropriate : 2 . Must prior treatment antiCD20 antibody therapy 3 . Must least one bidimensionally measurable lesion ≥1.5 cm ) document CT scan . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 5 . Life expectancy least 6 month 6 . Adequate bone marrow function document : 1 . Platelet count ≥75 x 109/L 2 . Hb level ≥9 g/dL 3 . ANC ≥1 x 109/L 7 . Adequate organ function 8 . Willing able comply clinic visit studyrelated procedure 9 . Provide sign informed consent Key 1 . Primary central nervous system ( CNS ) lymphoma know suspected CNS involvement nonprimary CNS NHL 2 . History current relevant CNS pathology 3 . Allogeneic stem cell transplantation 4 . Infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 5 . Known hypersensitivity allopurinol rasburicase . The information provide intend contain consideration relevant potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>